Select Page

Côte d’Ivoire

The Côte d’Ivoire Population-based HIV Impact Assessment (CIPHIA) began fieldwork in August 2017, concluded in March 2018, and announced results at the AIDS 2018 conference in Amsterdam.

In Côte d’Ivoire, survey teams visited approximately 10,000 households, interviewed participants, and provided HIV counseling and testing.

Key Findings

%

Annual HIV incidence among adults

%

HIV prevalence among children

%

Viral load suppression among adults living with HIV

90-90-90 among adults living with HIV
20%

Adults living with HIV reported they know their HIV status

75%

Adults who reported knowing their HIV-positive status also reported they were on ART

75%

Adults who reported being on ART had viral load suppression

Recent PHIA News
PHIA Gets a Royal Launch in Lesotho
PHIA Gets a Royal Launch in Lesotho
On November 20, 2019, Her Majesty Queen ‘Masenate Mohato Seeiso launched the second Lesotho Population-based HIV Impact Assessment survey (LePHIA 2020).
In Zimbabwe, When PHIA Knocked, Doors Opened
In Zimbabwe, When PHIA Knocked, Doors Opened
Over the past four months, a familiar refrain was heard throughout the cities, towns, and villages of Zimbabwe. The ‘Knock Knock’ song, which was instrumental to the success of the first Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) survey,  heralded the new survey and with the message of a new chance for the country to take stock of what has been achieved towards controlling its devastating HIV epidemic.
Survey Results Put Rwanda on Track to Achieve HIV Epidemic Control
Survey Results Put Rwanda on Track to Achieve HIV Epidemic Control
The Government of Rwanda, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the U.S. Centers for Disease Control and Prevention (CDC), and ICAP at Columbia University released new data today that demonstrate Rwanda’s remarkable progress toward achieving HIV epidemic control — particularly in attaining high levels of linkage to treatment and viral load suppression among people living with HIV.